FDA Aspergillosis Biomarker Qualification Highlights New Drug Development Tool Process
This article was originally published in RPM Report
Executive Summary
FDA’s new drug development qualification process offers a pathway for outside groups to gain acceptance of specific biomarkers for regulatory purposes. FDA recently used the process to qualify a specific biomarker for a severe fungal infection.